Supernus Pharmaceuticals Inc. (SUPN)
Supernus Pharmaceuticals: The Merger Is Priced Like A Retreat, But Reads Like A Reverse Takeover
Supernus Pharmaceuticals merges with Indivior, gaining operational control and exposure to a larger, cash-generating CNS and addiction platform. SUPN's growth products now comprise 80% of revenue, with Qelbree and ZURZUVAE driving robust prescription and sales growth. Combined entity targets $2.2B revenue, $888M adjusted EBITDA, $125M synergies, and trades at ~7x synergized EBITDA—suggesting a mispriced, underappreciated value.
Is the Options Market Predicting a Spike in Supernus Pharmaceuticals Stock?
Investors need to pay close attention to SUPN stock based on the movements in the options market lately.
SUPN vs. TEVA: Which Stock Should Value Investors Buy Now?
Investors with an interest in Medical - Generic Drugs stocks have likely encountered both Supernus Pharmaceuticals (SUPN) and Teva Pharmaceutical Industries Ltd. (TEVA). But which of these two stocks is more attractive to value investors?
Supernus Pharmaceuticals, Inc. (SUPN) M&A Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) M&A Call Transcript
Compared to Estimates, Supernus (SUPN) Q2 Earnings: A Look at Key Metrics
The headline numbers for Supernus (SUPN) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Supernus Pharmaceuticals Q2 Earnings Call Highlights
Supernus Pharmaceuticals NASDAQ: SUPN and Indivior Pharmaceuticals announced a proposed all-stock, tax-free merger of equals that would create a central nervous system-focused biopharmaceutical company with approximately $2.2 billion in pro forma trailing 12-month net revenue as of June 30, 2026.
Supernus Pharmaceuticals (SUPN) Matches Q2 Earnings Estimates
Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.54 per share, in line with the Zacks Consensus Estimate . This compares to earnings of $0.91 per share a year ago.
Supernus Pharmaceuticals (SUPN) Expected to Beat Earnings Estimates: Should You Buy?
Supernus (SUPN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Will Supernus (SUPN) Beat Estimates Again in Its Next Earnings Report?
Supernus (SUPN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Strength Seen in Supernus (SUPN): Can Its 5.2% Jump Turn into More Strength?
Supernus (SUPN) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Presents at Bank of America Global Healthcare Conference 2026 Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript
Supernus Pharmaceuticals, Inc. (SUPN) Q1 2026 Earnings Call Transcript
